Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

[1]  A. Schnapp,et al.  Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. , 2006, American journal of respiratory and critical care medicine.

[2]  S. Kudoh,et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.

[3]  Jian Li,et al.  Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. , 2004, Cytokine.

[4]  M. Bruss,et al.  Pharmacokinetics of orally administered pirfenidone in male and female beagles. , 2004, Journal of veterinary pharmacology and therapeutics.

[5]  H. Asao,et al.  Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. , 2004, American journal of respiratory cell and molecular biology.

[6]  H. Oku,et al.  Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis , 2004, European Respiratory Journal.

[7]  S. Phan,et al.  Bone marrow-derived progenitor cells in pulmonary fibrosis. , 2004, The Journal of clinical investigation.

[8]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[9]  E. White,et al.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis , 2003, The Journal of pathology.

[10]  Kazuhiko Yamamoto,et al.  Potential Action of IL-4 and IL-13 as Fibrogenic Factors on Lung Fibroblasts in vitro , 2003, International Archives of Allergy and Immunology.

[11]  H. Collard,et al.  Demystifying idiopathic interstitial pneumonia. , 2003, Archives of internal medicine.

[12]  S. Nagai,et al.  Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. , 2002, Internal medicine.

[13]  L. Newman,et al.  Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. , 2002, American journal of respiratory and critical care medicine.

[14]  J. Renauld,et al.  A Profibrotic Function of IL-12p40 in Experimental Pulmonary Fibrosis1 , 2002, The Journal of Immunology.

[15]  H. Oku,et al.  Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. , 2002, European journal of pharmacology.

[16]  R. Homer,et al.  Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1 , 2001, The Journal of experimental medicine.

[17]  G. Hunninghake,et al.  Idiopathic pulmonary fibrosis. , 2001, The New England journal of medicine.

[18]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[19]  D. Behera,et al.  Interferon-γ 1b: impact of new indications (idiopathic pulmonary fibrosis) , 2000 .

[20]  D. Hyde,et al.  Anti-Inflammatory Effect of Pirfenidone in the Bleomycin-Hamster Model of Lung Inflammation , 2000, Inflammation.

[21]  R. Ziesche,et al.  Mechanisms of antifibrotic action of interferon gamma-1b in pulmonary fibrosis. , 2000, Wiener klinische Wochenschrift.

[22]  Y. Kaneda,et al.  Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[23]  M. Yamakido,et al.  Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. , 2000, American journal of respiratory and critical care medicine.

[24]  V. Petkov,et al.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. , 1999, The New England journal of medicine.

[25]  S. Iyer,et al.  Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  S. Iyer,et al.  Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. , 1999, The Journal of pharmacology and experimental therapeutics.

[27]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. , 1999, American journal of respiratory and critical care medicine.

[28]  G. Gurujeyalakshmi,et al.  Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[29]  P. Zabel,et al.  Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis. , 1998, International journal of immunopharmacology.

[30]  T. Hosoya.  [Steroid resistance and lung-tissue cytokines in experimental bleomycin-induced lung fibrosis]. , 1997, Nihon Kyobu Shikkan Gakkai zasshi.

[31]  R. Rerko,et al.  In vivo production and function of IL-12 p40 homodimers. , 1997, Journal of immunology.

[32]  J. Kehrer,et al.  Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. , 1997, Toxicology letters.

[33]  L. Newman,et al.  Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. , 1996, The American journal of pathology.

[34]  D. Hyde,et al.  Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. , 1995, The Journal of laboratory and clinical medicine.

[35]  B. Rollins,et al.  Serologic analysis of the mouse beta chemokine JE/monocyte chemoattractant protein-1. , 1994, Journal of immunology.

[36]  O. Lesur,et al.  Interleukin-6, interferon-gamma, and phospholipid levels in the alveolar lining fluid of human lungs. Profiles in coal worker's pneumoconiosis and idiopathic pulmonary fibrosis. , 1994, Chest.

[37]  D. Danielpour,et al.  Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. , 1993, The Journal of clinical investigation.

[38]  Y. Kawabata,et al.  Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. , 1993, Chest.

[39]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[40]  M. Selman,et al.  Platelet-derived growth factor in idiopathic pulmonary fibrosis. , 1990, The Journal of clinical investigation.

[41]  P. Vassalli,et al.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis , 1989, The Journal of experimental medicine.

[42]  J M Simpson,et al.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale. , 1988, Journal of clinical pathology.

[43]  H. Umezawa,et al.  [Changes of anticancer activity and pulmonary toxicity of bleomycins in differences of administration schedules and routes in mice]. , 1984, Gan to kagaku ryoho. Cancer & chemotherapy.

[44]  B. Burrows,et al.  Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival , 1980, Thorax.

[45]  J. F. Woessner,et al.  The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. , 1961, Archives of biochemistry and biophysics.

[46]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[47]  A. Mauviel.  Transforming growth factor-beta: a key mediator of fibrosis. , 2005, Methods in molecular medicine.

[48]  H. Misra,et al.  Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals , 2004, Molecular and Cellular Biochemistry.

[49]  H. Okamura,et al.  Interleukin-18 regulates both Th1 and Th2 responses. , 2001, Annual review of immunology.

[50]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[51]  I. Lossos,et al.  The effect of enoxaparin on bleomycin-induced lung injury in mice. , 1999, Experimental lung research.

[52]  G. Gurujeyalakshmi,et al.  Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. , 1995, Experimental lung research.

[53]  A. Thomson.  The cytokine handbook , 1994 .

[54]  S. Kunkel,et al.  Lung cytokine production in bleomycin-induced pulmonary fibrosis. , 1992, Experimental lung research.

[55]  Katsutoshi Takahashi,et al.  Different Sensitivity to Bleomycin-Induced Pulmonary Fibrosis among Various Strains of Mice , 1987 .